While the combination of pembrolizumab with standard-of-care (SOC) radiation, and androgen deprivation therapy with or without olaparib (Lynparza) was found generally feasible in high-risk localized ...
Long-term follow-up shows that treatment with Empliciti plus pomalidomide and dexamethasone continues to significantly increase survival rates in patients with relapsed or refractory multiple myeloma, ...
There is an increasing need to evaluate innovative drugs for childhood cancer using combination strategies. Strong biological rationale and clinical experience suggest that multiple agents will be ...
As asthma symptoms worsen, patients typically rely on short-acting β 2-agonist (SABA) rescue therapy, but SABAs do not address worsening inflammation, which leaves patients at risk for severe asthma ...
Uterine fibroids are a common cause of heavy menstrual bleeding and pain. Treatment with the combination of relugolix (an oral gonadotropin-releasing hormone-receptor antagonist), estradiol, and ...
In the NeoSphere study, various combinations of a new HER2-targeted agent called pertuzumab, Herceptin and chemothery were studied in early-stage breast cancer patients with encouraging results. When ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results